230 related articles for article (PubMed ID: 10846280)
1. Primary and secondary prevention of cardiovascular disease in the elderly.
García-Palmieri MR
Bol Asoc Med P R; 2000; 92(1-3):3-8. PubMed ID: 10846280
[TBL] [Abstract][Full Text] [Related]
2. [Primary prevention of cardiovascular disease].
Gohlke H
Dtsch Med Wochenschr; 2005 Jan; 130(1-2):38-43. PubMed ID: 15619173
[No Abstract] [Full Text] [Related]
3. [Primary and secondary prevention of arteriosclerosis. Risk stratification of hypertension].
Gysan DB
Z Kardiol; 2002 Oct; 91(10):777-85. PubMed ID: 12395218
[TBL] [Abstract][Full Text] [Related]
4. Primary prevention of coronary heart disease in the elderly.
Dornbrook-Lavender KA; Pieper JA; Roth MT
Ann Pharmacother; 2003 Nov; 37(11):1654-63. PubMed ID: 14565805
[TBL] [Abstract][Full Text] [Related]
5. Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS).
Li JJ; Lu ZL; Kou WR; Chen Z; Wu YF; Yu XH; Zhao YC;
J Clin Pharmacol; 2009 Aug; 49(8):947-56. PubMed ID: 19602720
[TBL] [Abstract][Full Text] [Related]
6. Prevention for the older woman. A practical guide to managing cardiovascular disease.
Messinger-Rapport BJ; Thacker HL
Geriatrics; 2002 Jul; 57(7):22-6, 29-30. PubMed ID: 12134461
[TBL] [Abstract][Full Text] [Related]
7. [Lowering cholesterol in the elderly--yes, no, or maybe?].
Gogol M
MMW Fortschr Med; 2006 Mar; 148(12):40-3. PubMed ID: 16626005
[TBL] [Abstract][Full Text] [Related]
8. The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study.
Fossum E; Gleim GW; Kjeldsen SE; Kizer JR; Julius S; Devereux RB; Brady WE; Hille DA; Lyle PA; Dahlöf B
J Intern Med; 2007 Oct; 262(4):439-48. PubMed ID: 17875180
[TBL] [Abstract][Full Text] [Related]
9. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials.
Saha SA; Molnar J; Arora RR
J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):192-204. PubMed ID: 17875946
[TBL] [Abstract][Full Text] [Related]
10. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
[TBL] [Abstract][Full Text] [Related]
11. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
[TBL] [Abstract][Full Text] [Related]
12. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
[TBL] [Abstract][Full Text] [Related]
13. [Hypertension in the elderly].
Plouin PF; Rossignol P; Bobrie G
Bull Acad Natl Med; 2006; 190(4-5):793-805; discussion 806, 873-6. PubMed ID: 17195607
[TBL] [Abstract][Full Text] [Related]
14. Clinical trials in isolated systolic hypertension in the elderly.
García-Palmieri MR; Torrado JM
P R Health Sci J; 2003 Jun; 22(2):145-8. PubMed ID: 12866138
[TBL] [Abstract][Full Text] [Related]
15. [Type 2 diabetes and cardiovascular risk: lessons from therapeutic trials].
Lièvre M
Rev Prat; 2001 Oct; 51(16):1793-9. PubMed ID: 11795124
[TBL] [Abstract][Full Text] [Related]
16. Statins for stroke prevention: disappointment and hope.
Amarenco P; Tonkin AM
Circulation; 2004 Jun; 109(23 Suppl 1):III44-9. PubMed ID: 15198966
[TBL] [Abstract][Full Text] [Related]
17. [Prevention of cardiovascular complications after a stroke or TIA: hypotensive and hypocholesterolemic therapy].
Dippel DW; van der Worp HB
Ned Tijdschr Geneeskd; 2004 Apr; 148(17):820-4. PubMed ID: 15141647
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in the secondary prevention of coronary heart disease.
Veverka A; Jolly JL
Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):877-89. PubMed ID: 15500433
[TBL] [Abstract][Full Text] [Related]
19. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
Oparil S; Bakir SE
Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
[TBL] [Abstract][Full Text] [Related]
20. Effect of xuezhikang on cardiovascular events and mortality in elderly patients with a history of myocardial infarction: a subgroup analysis of elderly subjects from the China Coronary Secondary Prevention Study.
Ye P; Lu ZL; Du BM; Chen Z; Wu YF; Yu XH; Zhao YC;
J Am Geriatr Soc; 2007 Jul; 55(7):1015-22. PubMed ID: 17608873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
